Donanemab: First Approval
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody that is being developed by Eli Lilly and Company for the treatment of Alzheimer’s disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer’s disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer’s disease.
© Springer Nature Switzerland AG 2024
